Introduction {#s1}
============

Gouty arthritis is a metabolic disease caused by the deposition of monosodium urate crystals in joints and soft tissues ([@B16]) and closely associated with chronic hyperuricemia, which seriously affects quality of life of patients due to severe pain ([@B15]). Across the globe, the age of onset is getting younger and younger ([@B23]). It is estimated that the number of gout patients in China will exceed 100 million in 2020. Now, gout has become the second largest metabolic disease in China ([@B19]).

At present, western medicines including colchicine, allopurinol, benzbromarone, and febuxostat have been used as the conventional therapy method for gouty arthritis. Although their short-term effect on inhibiting uric acid production, promoting uric acid excretion, or analgesic effect is optimistic, the side effects such as skin mucosal injury, kidney and liver injury, digestive tract injury, as well as some potential neurotoxicity and muscular toxicity caused by long-term use could not be ignored. Meanwhile, as the main form of traditional Chinese medicine (TCM) that based on the compatibility theory, traditional Chinese herbal formula has been applied for the treatment of gouty arthritis for thousands of years in view of remarkable therapeutic effect and little adverse reactions ([@B23]).

Jiang-Suan-Chu-Bi recipe (JSCBR) is a formula prescribed according to utilization frequency and cluster analysis by retrieving gout-related data obtained from multiple databases ([@B21]), which has been clinically validated remedy for gouty arthritis under the guidance of TCM doctors. It consists of 12 herbs, namely, Smilax glabra Roxb. (tu-fu-ling in Chinese, TFL, batch No. 20160925), Paeonia lactiflora Pall (chi-shao in Chinese, CS, batch No. 20160814), Reynoutria japonica Houtt. (hu-zhang in Chinese, HZ, batch No. 20160728), Cremastra appendiculata (D.Don) Makino (shan-ci-gu in Chinese, SCG, batch No. 20160723), Rheum officinale Baill. (da-huang in Chinese, DH, batch No. 20160719), Clematis chinensis Osbeck (wei-ling-xian in Chinese, WLX, batch No. 20160915), Angelica pubescens Maxim. (du-huo in Chinese, Dh, batch No. 20160822), Phellodendron chinense C.K.Schneid. (huang-bai in Chinese, HB, batch No. 20160918), Atractylodes lancea (Thunb.) DC. (cang-zhu in Chinese, CZ, batch No. 20160814), Glycyrrhiza glabra L. (gan-cao in Chinese, GC, batch No. 20160816), Codonopsis pilosula (Franch.) Nannf. (dang-shen in Chinese, DS, batch No. 20160723), and Angelica sinensis (Oliv.) Diels (dang-gui in Chinese, DG, batch No. 20160801). Although its prescription is scientific and the efficacy is definite. To date, no reports on the chemical composition and functional mechanisms of JSCBR contribute to its bioactivity has been published, which restrict its further application and development.

In the present study, a systematic dissection of JSCBR was employed by integrating chemical profile, network pharmacology, and experimental support using molecular cell biology. The schematic diagram of the present study was depicted in [**Figure 1**](#f1){ref-type="fig"}.

![The schematic diagram of the present study.](fphar-10-01626-g001){#f1}

Materials and Methods {#s2}
=====================

Chemicals, Reagents, and Materials {#s2_1}
----------------------------------

UHPLC-MS grade acetonitrile and methanol were supplied by Merck Company Inc., (Darmstadt, Germany). MS grade formic acid was purchased from Fisher Scientific Company (Inc., Fairlawn, NJ). Ultrapure water (18.2 MΩ) was prepared with a Milli-Q water purification system (Millipore, Milford, MA, USA). All other reagents were of analytical grade and purchased from Tianjin Concord Technology Co. Ltd. (Tianjin, China).

The reference compounds ferulic acid (**56**), polydatin (**57**), paeoniflorin (**79**), atractylodin (**81**), liquiritin (**84**), aloe-emodin (**94**), rhein (**115**), glycyrrhizic acid (**119**), osthole (**126**), columbianadin (**127**), and oleanolic acid (**134**) were purchased from Chengdu Pufei De Biotech (Chengdu, Sichuan, China). The reference compounds astilbin (**60**), chysophanol (**93**), physcion (**100**), and emodin (**122**) were purchased from Baoji Herbest Biotech (Baoji, Shanxi, China). The purity of each reference standard was determined to be over 98% by UHPLC analysis. All the 12 herbs of JSCBR were purchased from Beijing Tong-Ren-Tang Technologies Co., Ltd. (Taiyuan, Shanxi Province, China), and authenticated by Professor Yunpeng Diao (College of Pharmacy, Dalian Medical University). Voucher specimens were deposited at the authors' laboratory.

THP-1 cell was purchased from Yipu Biological Technology Co., Ltd. (Wuhan, Hubei Province, China). RPMI 1640 cell culture mediums and pencillin-streptomycin were purchased from Gibco BRL, Invitrogen Corporation (Grand Island, NY). Fetal bovine serum was purchased from Zhejiang Tianhang Biotechnology Co., Ltd. (Hangzhou, Zhejiang Province, China). Cell Counting Kit -8 (CCK-8) was purchased from Yiyuan Biotechnology Co., Ltd. (Guangzhou, Guangdong Province, China). Phorbol-12-myristate-13-acetate (PMA) was purchased from Abcam Ltd., (Cambridge, UK). Monosodium urate (MSU) was purchased from Sigma-Aldrich (St Louis, MO, USA). Colchicine was supplied by Shengshi Kangpu Chemical Technology Research Institute (Beijing, China). Antibodies against caspase-1, β-actin, apoptosis-associated speck-like protein (ASC), IL-1β, and antirabbit IgG-HRP were purchased from Bioss (Beijing, China). The BCA Protein Quantification Kit was purchased from KeyGen Biotech Co., Ltd. (Nanjing, Jiangsu Province, China). RIPA lysis buffer and PMSF protease inhibitor were purchased from Beyotime Institute of Technology (Shanghai, China). ECL-plus chemiluminescence reagent was purchased from Bio-rad (Richmond, CA, USA).

Preparation of JSCBR Extract {#s2_2}
----------------------------

The usage of each crude herb were accurately weighed as follows: Smilacis Glabrae Rhizome (30 g), Paeoniae Radix Rubra (10 g), Polygoni Cuspidati Rhizoma et Radix (15 g), Cremastrae Pseudobulbus (8 g), Rhei Radix et Rhizoma (10 g), Clematidis Radix et Rhizome (15 g), Angelicae Pubescentis Radix (10 g), Phellodendri Chinensis Cortex (10 g), Atractylodis Rhizome (10 g), Glycyrrhizae Radix et Rhizome (10 g), Codonopsis Radix (15 g), and Angelicae Sinensis Radix (10 g). They were mixed and prepared by the decocting method as described below: a total of 153 g mixture was immersed in sevenfold mass of water for 2 h, heated and refluxed for 2 h and then filtered with six-layer absorbent gauze. A fivefold mass of water was subsequently added to the residues and boiled for 2 h. After being filtered with six-layer absorbent gauze, the two filters were combined and concentrated to 150 ml (equal to 1 g crude herb/ml). The liquid was finally transformed into powder by vacuum freeze drying technology.

A 1.0 g of the freeze-dried powder was accurately weighted and extracted with 50 ml of methanol/water (1:1, v/v) for 30 min under ultrasound. The extract solution was centrifuged at 13,000 rpm for 10 min at 4°C and the supernatant was filtered through a 0.22 μm membrane filters. 1.0 μl of filtrate was injected to UHPLC-QTOF-MS for analysis.

UHPLC-QTOF-MS Analysis {#s2_3}
----------------------

The chromatography and MS conditions were almost the same as those reported in literature ([@B7]). The only difference is the change of elution gradient, which was listed as follows: 0--25 min, 5%--45% B; 25--35 min, 45%--99% B; 35--38 min, 99%--5% B; 38--40 min, 5% B.

Establishment of In-House Library for JSCBR and Generation of Empirical Molecular Formula {#s2_4}
-----------------------------------------------------------------------------------------

The in-house library that covers all previous reported compounds from the 12 formulated herbs was established in a Microsoft office excel table, which includes compound name, molecular formula, molecular weight, chemical structures, natural source, and related references ([@B2]; [@B10]; [@B4]; [@B13]; [@B1]; [@B5]; [@B6]; [@B17]; [@B12]; [@B18]; [@B22]). The empirical molecular formula that matched the criterion for ppm below 10 were deduced as potential candidates by the function "Find Compounds by Formula" of Agilent MassHunter qualitative analysis software. Only those compounds that had been compared with standards or characteristic fragment ions were finally selected as chemical composition of JSCBR.

Network Pharmacology Analysis {#s2_5}
-----------------------------

### Identification of Candidate Targets of Gouty Arthritis {#s2_5_1}

Gouty arthritis related targets were acquired from seven existing resources: 1. TTD database (<http://bidd.nus.edu.sg/BIDD-Databases/TTD/TTD.asp>); 2. OMIM database (<http://omim.org/>); 3. PharmGKB database (<https://www.pharmgkb.org/>); 4. DrugBank database (<http://www.drugbank.ca/>, version 4.3); 5. GAD database (<https://geneticassociationdb.nih.gov/>); 6. DisGeNET database (<http://www.disgenet.org/web/DisGeNET/menu>); 7. GeneCards database (<https://www.genecards.org/>). We searched these databases and acquired 175 genes totally after removing duplicates. The detailed information is provided in [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}.

### Identification of Compound Targets of JSCBR {#s2_5_2}

After identifying the compounds contained in JSCBR by UHPLC-QTOF-MS, the CAS number and Canonical SMILES were collected by PubChem Compound (<https://www.ncbi.nlm.nih.gov/pccompound/>). In order to get as many targets as possible, two databases were employed to this study, including Swiss Target Prediction (<http://www.swisstargetprediction.ch/>) and Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, <http://lsp.nwu.edu.cn/tcmsp.php>). Then, the gene information including name, gene ID, and organism was confirmed using UniProt (<http://www.uniprot.org/>). The final selected genes are supplied in [**Supplementary Table S2**](#SM2){ref-type="supplementary-material"}.

### The Protein-Protein Interactions (PPIs) Network Analysis of Disease Targets {#s2_5_3}

The protein-protein interactions (PPIs) network of gouty arthritis was constructed and analyzed by STRING database. Those PPIs with high confidence score (\>0.95) should be selected for network construction and analysis to ensure the accuracy of the results.

Network Construction and Analysis {#s2_6}
---------------------------------

All the networks can be performed by employing the network visualization software Cytoscape 3.2.1. Three networks were constructed as follows: (1) PPIs of gouty arthritis targets; (2) Compound-potential targets-disease network analysis; (3) Pathways-targets network analysis. In these network plots, nodes represent herbs and chemicals, and edges indicate interactions between different chemicals, targets, and pathways. The "degree" of a node was defined as the number of its connected edges.

Enrichment Analysis {#s2_7}
-------------------

To clarify the signaling pathways and functions of potential target genes, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichments analysis was performed based on Database for Annotation, Visualization and Integrated Discovery (DAVID, <https://david.ncifcrf.gov/home.jsp>, ver. 6.8) and STRING.

Experimental Validation Using Molecular Cell Biology {#s2_8}
----------------------------------------------------

### Cell Culture {#s2_8_1}

Human monocytic leukemia THP-1 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 μg/ml). Cells were maintained in an incubator at 37˚C with 5% CO~2~ and saturated humidity and the culture medium was replaced with complete culture medium every 2 or 3 days.

### CCK-8 Assay for Cell Viability {#s2_8_2}

THP-1 cells were harvested during the logarithmic growth phase and seeded into a 96-well plate at a density of 1x10^6^ cells/well with a final volume of 100 μl. The cells were treated with PMA (100 nM) for 3 h to induce their differentiation into resting M0 macrophage. Fresh complete culture medium was added and cultured for 24 h after washing the cells with PBS solution. Differentiated THP-1 cells were then stimulated with MSU (100, 150, 200, 300, 400, and 500 μg/ml) with optimal concentration and treated with JSCBR extracts at final concentrations of 1, 2, 3, 4, and 5 mg/ml as well as colchicine (positive drug, 2 μg/ml) simultaneously at 37˚C for 24 h ([@B9]). After treatment, 10 μl of CCK-8 was added to each well, and the plates were then incubated for additional 1.5 h. The absorbance at 450 nm was measured using 600 nm as a reference wavelength, which performed on a SpectraMax M2 reader (Molecular Devices, Silicon Valley, USA), and culture medium without cell was used as a blank. The experiments were performed in triplicate and repeated at least twice. The cell viability was calculated using the following formula:
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where A~s~, A~b~, and A~c~ represent the absorbance difference of experimental, blank, and control groups, respectively.

### Western Blot Analysis {#s2_8_3}

Total protein was extracted by incubation of cell pellet with RIPA lysis buffer and PMSF protease inhibitor. The protein concentration was determined by the BCA Protein Quantification Kit according to the instructions of manufacturer. The cell lysate containing 68 μg of protein was fractionated by 10% SDS-PAGE and then transferred to a poly (vinylidene difluoride) (PVDF) membrane. After blocking with 5% nonfat milk in Tris-buffered saline containing 0.1% Tween-20 at room temperature for 2 h, the membrane was incubated with primary antibodies at 4˚C overnight and horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature, respectively. Protein bands were probed with an ECL Plus chemiluminescence reagent and exposed to a Tanon-5200 Imaging System (Tanon, Shanghai, China).

### Statistical Analysis {#s2_8_4}

Data are presented as means ± SD for three independent experiments. Statistical differences between two groups were analyzed using a Student's t test by GraphPad Prism 5.0 (San Diego, CA, USA). A significant difference was considered as P \< 0.05.

Results {#s3}
=======

Chemical Profile of JSCBR by UHPLC-QTOF-MS {#s3_1}
------------------------------------------

In the present study, a specific UHPLC-QTOF-MS protocol was performed to rapidly identify the compounds of JSCBR as many as possible after optimizing the LC and MS conditions systemically. As a result, a total of 139 compounds, including 39 phenolic acids, 19 flavonoids, 13 triterpenoid saponins, 11 alkaloids, 10 amino acids, 10 fatty acids, 8 anthraquinones, 8 terpenes, 6 coumarins, and 15 miscellaneous compounds were identified or tentatively characterized ([**Figure 2**](#f2){ref-type="fig"}, [**Table 1**](#T1){ref-type="table"}).

![Representative base peak chromatogram (BPC) of Jiang-Suan-Chu-Bi recipe (JSCBR) in the positive and negative ions mode, respectively.](fphar-10-01626-g002){#f2}

###### 

Characterization of the chemical constituents in Jiang-Suan-Chu-Bi recipe (JSCBR) by ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS).

  Peak No     t~R~ (min)   Identification                               Formula ion          Negative ion          Positive ion   Source *^a^*                                                      
  ----------- ------------ -------------------------------------------- -------------------- --------------------- -------------- -------------- ------ -------------- ---------- ---------- ------ -----------------
  1           0.766        Arginine                                     C~6~H~14~N~4~O~2~    \[M-H\] ^--^          173.1044       173.1044       -2.8   \[M+H\] ^+^    175.1191   175.1190   -0.6   GC/DS/DG
  2           0.799        Fructose                                     C~6~H~12~O~6~        \[M-H\] ^--^          179.0566       179.0561       -2.8   ---            ---        ---        ---    DG
  3           0.804        Pulegone                                     C~10~H~16~O          ---                   ---            ---            ---    \[M+Na\] ^+^   175.1098   175.1093   -2.9   DS
  4           0.816        Hypoxanthine                                 C~5~H~4~N~4~O        \[M+CH~3~COO\] ^--^   195.0517       195.0524       3.6    ---            ---        ---        ---    DG
  5           0.853        Proline                                      C~5~H~9~NO~2~        \[M-H\] ^--^          114.0539       114.0561       19.3   \[M+H\] ^+^    116.0694   116.0706   10.3   GC/DG
  6           0.866        Atractylenolide III sulfate                  C~15~H~20~O~6~S      \[M+CH~3~COO\] ^--^   387.1152       387.1119       -8.5                                               DS
  7           1.031        Malic acid                                   C~4~H~6~O~5~         \[M-H\] ^--^          133.0148       133.0142       -4.5   ---            ---        ---        ---    CZ
  8           1.268        Pyroglutamic acid                            C~5~H~7~NO~3~        ---                   ---            ---            ---    \[M+H\] ^+^    130.0499   130.0499   0      GC/SCG
  9           1.350        Tyrosine                                     C~9~H~11~NO~3~       ---                   ---            ---            ---    \[M+H\] ^+^    182.0794   182.0812   9.9    GC/SCG/DG
  10          1.384        Adenosine                                    C~10~H~13~N~5~O~4~   ---                   ---            ---            ---    \[M+H\] ^+^    268.1040   268.1040   0      Dh/SCG/HB/DS/DG
  11          1.429        Guanosine                                    C~10~H~13~N~5~O~5~   \[M-H\] ^--^          282.0859       282.0844       -5.3   \[M+H\] ^+^    284.1001   284.0989   -4.2   DG
  12          1.479        Succinic acid                                C~4~H~6~O~4~         \[M-H\] ^--^          117.0193       117.0193       0      ---            ---        ---        ---    DS/SCG/DG
  13          1.483        Guanine                                      C~5~H~5~N~5~O        ---                   ---            ---            ---    \[M+H\] ^+^    152.0558   152.0567   5.9    DG
  14          1.545        Galloyl glucose                              C~13~H~16~O~10~      \[M-H\] ^--^          331.0684       331.0671       -3.9   ---            ---        ---        ---    DH
  15          1.715        Leucine                                      C~6~H~13~NO~2~       \[M-H\] ^--^          130.0874       130.0874       0      \[M+H\] ^+^    132.1021   132.1019   -1.5   DG
  16          1.794        Gallic acid                                  C~7~H~6~O~5~         \[M-H\] ^--^          169.0146       169.0142       -2.4   \[M+H\] ^+^    171.0288   171.0288   0      CS/DG
  17          1.976        Gastrodine                                   C~13~H~18~O~7~       \[M+HCOO\] ^--^       331.1037       331.1035       -0.6   ---            ---        ---        ---    SCG
  18          2.357        Gallic acid -O-diglucoside                   C~19~H~26~O~15~      \[M-H\] ^--^          493.1211       493.1199       -2.4   ---            ---        ---        ---    DH
  19          3.335        Woodorien                                    C~14~H~18~O~9~       \[M-H\] ^--^          329.0890       329.0878       -3.6   ---            ---        ---        ---    DS
  20          3.621        9,10-dihydro-2-methyl-anthracen              C~15~H~14~           ---                   ---            ---            ---    \[M+H\] ^+^    195.1169   195.1168   -0.5   HZ
  21          3.870        Codonopsine                                  C~14~H~21~NO~4~      ---                   ---            ---            ---    \[M+H\] ^+^    268.1503   268.1543   14.9   DS
  22          4.130        Catechin 7-O-β-D-glucopyranoside             C~21~H~24~O~11~      \[M-H\] ^--^          451.1258       451.1246       -2.7   ---            ---        ---        ---    DH
  23          6.383        Chlorogenic acid                             C~16~H~18~O~9~       \[M-H\] ^--^          353.0891       353.0878       -3.7   ---            ---        ---        ---    DG/HB
  24          5.080        Tryptophan                                   C~11~H~12~N~2~O~2~   \[M-H\] ^--^          203.0832       203.0826       -3     \[M+H\] ^+^    205.0952   205.0972   9.8    DS/DG
  25          5.472        p-Hydroxybenzyl malonic acid                 C~10~H~10~O~5~       \[M-H\] ^--^          209.0462       209.0455       -3.3   ---            ---        ---        ---    GC
  26          5.472        Paeonol                                      C~9~H~10~O~3~        \[M-H\] ^--^          165.0561       165.0557       -2.4   ---            ---        ---        ---    CS
  27          5.494        Emodin-O-(O-acetyl)-glucopyranoside          C~23~H~22~O~11~      ---                   ---            ---            ---    \[M+H\] ^+^    475.1226   475.1235   1.9    DH
  28          6.234        (-)-epicatechin                              C~15~H~14~O~6~       \[M-H\] ^--^          289.0727       289.0718       -3.1   \[M+H\] ^+^    291.0850   291.0863   4.5    DH/TFL
  29          4.478        Neochlorogenic acid                          C~16~H~18~O~9~       \[M-H\] ^--^          353.0891       353.0878       -3.7   ---            ---        ---        ---    HB
  30          6.649        digalloyl-glucoside                          C~27~H~24~O~18~      \[M-H\] ^--^          635.0905       635.0890       -2.4   ---            ---        ---        ---    DH
  31          6.654        Umbelliferone                                C~9~H~6~O~3~         ---                   ---            ---            ---    \[M+H\] ^+^    163.0381   163.0390   5.5    Dh
  32          6.897        Cryptochlorogenin acid                       C~16~H~18~O~9~       \[M-H\] ^--^          353.0891       353.0878       -3.7   \[M+H\] ^+^    355.1017   355.1024   2      HB
  33          6.947        3-O-Feruloylquinic acid                      C~17~H~20~O~9~       \[M-H\] ^--^          367.1046       367.1035       -3     ---            ---        ---        ---    HB
  34          6.947        Berberrubine                                 C~19~H~16~NO~4~      \[M+HCOO\] ^--^       367.1052       367.1061       2.5    ---            ---        ---        ---    HB
  35          7.046        Caffeic acid                                 C~9~H~8~O~4~         \[M-H\] ^--^          179.0357       179.0350       -3.9   \[M+H\] ^+^    181.0484   181.0495   6.1    DG
  36          7.212        Vanillic acid                                C~8~H~8~O~4~         \[M-H\] ^--^          167.0354       167.0350       -2.4   \[M+H\] ^+^    169.0490   169.0495   3      DG/DS/SCG
  37          7.267        O-(O-methoxyphenoxy) phenol                  C~13~H~12~O~3~       ---                   ---            ---            ---    \[M+H\] ^+^    217.0871   217.0859   -5.5   DS
  38          8.223        Isomer of liquiritin-O-glucoside             C~32~H~40~O~18~      \[M-H\] ^--^          711.2143       711.2142       -0.1   ---            ---        ---        ---    GC
  39          8.510        (+)-Catechin                                 C~15~H~14~O~6~       \[M-H\] ^--^          289.0727       289.0718       -3.1   \[M+H\] ^+^    291.0850   291.0859   4.5    DG/DH/TFL
  40          8.643        (p-Hydroxybenzul)-6,7-dihydroxy-             C~23~H~29~NO~8~      ---                   ---            ---            ---    \[M+H\] ^+^    448.1957   448.1966   2      HB
                           N-metylterahydroisoquinoline-7-O-                                                                                                                                        
                           β-D-glucopyranoside                                                                                                                                                      
  41          8.659        7-O-Glucoptranoside of 1-(p-hydroxy          C~23~H~30~NO~8~      ---                   ---            ---            ---    \[M^+^H\]^+^   449.2013   449.2044   6.9    HB
                           benzyl)-6,7-dihydroxy-N-methylisoquinoline                                                                                                                               
  42          8.703        Kaempferol-3-O-rutinose                      C~27~H~30~O~15~      \[M-H\] ^--^          593.1541       593.1512       -4.9   ---            ---        ---        ---    DG
  43          8.803        Phellodendrine                               C~20~H~24~NO~4~      \[M+CI\] ^--^         376.1331       376.1321       -2.7   ---            ---        ---        ---    HB
  44          9.035        Hexyl-β-D-glucoside sulfate                  C~12~H~24~O~9~S      \[M+CH~3~COO\] ^--^   403.1250       403.1280       7.4    ---            ---        ---        ---    DS
  45          9.057        Apigenin-6,8-di-C-β-D-glucopyranoside        C~27~H~30~O~15~      ---                   ---            ---            ---    \[M+H\]^+^     595.1645   595.1657   2      GC
  46          9.140        Tetrehydropalmatrubine                       C~20~H~23~NO~4~      \[M-H\] ^--^          340.1497       340.1554       16.8   \[M+H\]^+^     342.1690   342.1700   2.9    HB
  47          9.233        Amurenlaetone B                              C~17~H~20~O~9~       \[M-H\] ^--^          367.1045       367.1035       -2.7   ---            ---        ---        ---    HB
  48          9.538        1-O-galloyl-2-O-cinnamoyl-β-D-glucose        C~22~H~22~O~11~      ---                   ---            ---            ---    \[M+H\] ^+^    463.1225   463.1235   2.2    DH
  49          9.797        Albiflorin                                   C~23~H~28~O~11~      \[M+HCOO\] ^--^       525.1634       525.1614       -3.8   ---            ---        ---        ---    CS/DG
  50          9.797        Benzoylpaeoniflorin                          C~24~H~24~O~10~      \[M+HCOO\] ^--^       517.1324       517.1351       5.2    ---            ---        ---        ---    DG
  51          10.151       4-Hydroxy-3-methyl-acetophenone              C~9~H~10~O~2~        ---                   ---            ---            ---    \[M+H\] ^+^    151.0740   151.0754   9.3    CS/Dh
  52          10.350       Isoliensinine                                C~19~H~23~NO~3~      \[M-H\] ^--^          312.1613       312.1605       -2.6   \[M+H\] ^+^    314.1743   314.1751   2.5    HB
  53          10.592       Galloylpaeoniflorin                          C~34~H~28~O~22~      \[M-H\] ^--^          787.1008       787.0999       -1.1   ---            ---        ---        ---    CS
  54          10.625       Cyclohexanecarboxylic acid                   C~17~H~20~O~9~       ---                   ---            ---            ---    \[M+H\] ^+^    369.1165   369.1180   4.1    HB
  55          10.830       Astragaloside V/VI/VII                       C~26~H~28~O~13~      ---                   ---            ---            ---    \[M+H\] ^+^    549.1595   549.1603   1.5    DG
  56 *^b^*    10.973       Ferulic acid                                 C~10~H~10~O~4~       \[M-H\] ^--^          193.0510       193.0506       -2.1   \[M+H\] ^+^    195.0644   195.0652   4.1    DG/Dh/HB/DS
  57 *^b^*    10.975       Polydatin                                    C~20~H~22~O~8~       \[M-H\] ^--^          389.1258       389.1242       -4.1   ---            ---        ---        ---    HZ
  55          10.830       Astragaloside V/VI/VII                       C~26~H~28~O~13~      ---                   ---            ---            ---    \[M+H\] ^+^    549.1595   549.1603   1.5    DG
  56 *^b^*    10.973       Ferulic acid                                 C~10~H~10~O~4~       \[M-H\] ^--^          193.0510       193.0506       -2.1   \[M+H\] ^+^    195.0644   195.0652   4.1    DG/Dh/HB/DS
  57 *^b^*    10.975       Polydatin                                    C~20~H~22~O~8~       \[M-H\] ^--^          389.1258       389.1242       -4.1   ---            ---        ---        ---    HZ
  58          11.029       Atractylenolide III                          C~15~H~20~O~3~       ---                   ---            ---            ---    \[M+H\] ^+^    249.1469   249.1485   6.4    CZ/DS
  59          11.404       Raffinose                                    C~18~H~32~O~16~      \[M+HCOO\] ^--^       549.1632       549.1672       7.3    ---            ---        ---        ---    DS
  60 *^b^*    11.470       Astilbin                                     C~21~H~22~O~11~      \[M-H\] ^--^          449.1109       449.1089       -4.5   \[M+H\] ^+^    451.1228   451.1235   1.6    TFL
  61          11.570       Cinnamic acid                                C~9~H~8~O~2~         \[M-H\] ^--^          147.0450       147.0452       1.4    \[M+H\] ^+^    149.0588   149.0597   6      SCG
  62          11.725       Liquiritigenin                               C~15~H~12~O~4~       ---                   ---            ---            ---    \[M+H\] ^+^    257.0800   257.0808   3.1    GC
  63          11.818       (+/-)-8-(4-Hydroxy-3-methoxyphenyl)-         C~27~H~36~O~13~      \[M-H\] ^--^          567.2095       567.2083       -2.1   ---            ---        ---        ---    HB
                           6,7-bis(hydroxymethyl)-3-methoxy-5,6,                                                                                                                                    
                           7,8-tetrahydro-2-naphthalenyl-β-D-                                                                                                                                       
                           glucopyranoside                                                                                                                                                          
  64          12.017       Ferulic acid-1-O-glucoside                   C~16~H~20~O~9~       \[M-H\] ^--^          355.1047       355.1035       -3.4   ---            ---        ---        ---    DH
  65          12.166       Galloylpaeoniflorinb                         C~30~H~32~O~15~      \[M-H\] ^--^          631.1678       631.1668       -1.6   ---            ---        ---        ---    DG
  66          12.289       Taxifolin                                    C~15~H~12~O~7~       ---                   ---            ---            ---    \[M+H\] ^+^    305.0645   305.0656   3.6    TFL
  67          12.769       Galloyl cinnamoyl-glucose                    C~22~H~22~O~11~      ---                   ---            ---            ---    \[M+H\] ^+^    463.1229   463.1235   1.3    DH
  68          13.078       Quercitrin                                   C~21~H~20~O~11~      \[M-H\] ^--^          447.0944       447.0933       -2.5   ---            ---        ---        ---    TFL
  69          13.084       Oxidized jatrorrhizine                       C~20~H~17~NO~5~      ---                   ---            ---            ---    \[M+H\] ^+^    352.1169   352.1179   2.8    HB
  70          13.160       Laccaic acid D-O-glucose                     C~22~H~20~O~12~      \[M-H\] ^--^          475.0897       475.0882       -3.2   ---            ---        ---        ---    DH
  71          13.283       Isomer of liquiritin apioside                C~25~H~24~O~11~      ---                   ---            ---            ---    \[M+H\] ^+^    501.1400   501.1391   -1.8   GC
  72          13.310       Engeletin                                    C~21~H~22~O~10~      \[M-H\] ^--^          433.1152       433.1140       -2.8   ---            ---        ---        ---    TFL
  73          13.343       Procyanidine/isomer                          C~16~H~20~O~9~       \[M-H\] ^--^          355.1047       355.1035       -3.4   ---            ---        ---        ---    DH
  74          13.359       Resveratrol-4-O-β-D-(2′-O-galloyl)-          C~27~H~26~O~12~      \[M-H\] ^--^          541.1367       541.1351       -3     ---            ---        ---        ---    DH
                           glucopyranoside or resveratrol-4-O-β-                                                                                                                                    
                           D-(6′-O-galloyl)-glucopyranoside                                                                                                                                         
  75          13.558       Dactylorhin A                                C~40~H~56~O~22~      \[M-H\] ^--^          887.3196       887.3190       -0.7   ---            ---        ---        ---    SCG
  76          13.581       Columbianetin                                C~14~H~14~O~4~       ---                   ---            ---            ---    \[M+H\] ^+^    247.0956   247.0965   3.6    Dh
  77          13.790       Azelaic acid                                 C~9~H~16~O~4~        \[M-H\] ^--^          187.0982       187.0976       -3.2   ---            ---        ---        ---    DS
  78          13.989       (6aR, 11aR)-3-hydroxy-9, 10-dimethoxy-       C~25~H~24~O~12~      \[M-H\] ^--^          515.1209       515.1195       -2.7   ---            ---        ---        ---    DG
                           pterocarpan-3-O-β-D-glc-6′′-O-malonate                                                                                                                                   
  79 *^b^*    14.394       Paeoniflorin                                 C~23~H~28~O~11~      ---                   ---            ---            ---    \[M+H\] ^+^    481.1570   481.1704   27.8   CS
  80          14.510       3-methoxy-4-hydroxyphenylethanol             C~9~H~12~O~3~        ---                   ---            ---            ---    \[M+Na\] ^+^   191.0692   191.0679   -6.8   SCG
  81 *^b^*    14.718       Atractylodin                                 C~13~H~10~O          \[M+HCOO\] ^--^       227.0721       227.0714       -3.1   ---            ---        ---        ---    CZ
  82          14.990       Aloe-emodin-8-O-β-D-glucopyranoside          C~21~H~20~O~10~      ---                   ---            ---            ---    \[M+Na\] ^+^   455.0948   455.0949   0.2    DH
  83          15.182       1-O-galloyl-2-O-cinnamoyl-β-D-glucose        C~22~H~22~O~11~      \[M-H\] ^--^          461.1105       461.1089       -3.5   ---            ---        ---        ---    DH
  84 *^b^*    15.265       Liquiritin                                   C~21~H~22~O~9~       \[M-H\] ^--^          417.1157       417.1191       8.2    \[M+H\] ^+^    419.1332   419.1337   1.2    GC
  85          15.281       Acetyl-liquiritin/isoliquiritin              C~23~H~24~O~10~      \[M-H\] ^--^          459.1306       459.1297       -2     ---            ---        ---        ---    GC
  86          15.935       Ononin                                       C~22~H~22~O~9~       ---                   ---            ---            ---    \[M+H\] ^+^    431.1306   431.1337   7.2    DG/GC
  87          16.160       Licorice glycoside B                         C~35~H~36~O~15~      \[M-H\] ^--^          695.1989       695.1981       -1.2   ---                                         GC
  88          16.482       Hexyl-b-D-glucopyranosyl-(1/6)-β-D-          C~18~H~34~O~11~      ---                   ---            ---            ---    \[M+H\] ^+^    427.2146   427.2174   6.8    DS
                           glucopyranoside                                                                                                                                                          
  89          16.524       Militarine                                   C~34~H~46~O~17~      \[M-H\] ^--^          725.2670       725.26662      -1.1   ---            ---        ---        ---    SCG
  90          16.988       Cinnamic-O-galloyl-glucoside                 C~22~H~22~O~11~      \[M-H\] ^--^          461.1104       461.1089       -3.3   ---            ---        ---        ---    DH
  91          18.181       Isoengeletin                                 C~21~H~21~O~10~      \[M-H\] ^--^          432.1029       432.1062       7.6    ---            ---        ---        ---    TFL
  92          18.222       Senkyunolide H                               C~12~H~16~O~4~       ---                   ---            ---            ---    \[M+Na\] ^+^   247.0958   247.0941   -6.9   DG
  93 *^b^*    18.413       Chrysophanol                                 C~15~H~10~O~4~       \[M-H\] ^--^          253.0509       253.0506       -1.2   \[M+H\] ^+^    255.0642   255.0652   3.9    DH/SCG
  94 *^b^*    18.520       Aloe-emodin                                  C~15~H~10~O~5~       ---                   ---            ---            ---    \[M+H\] ^+^    271.0596   271.0601   1.8    DH
  95          19.291       22-Acetoxyl licorice-saponin G2              C~44~H~64~O~19~      \[M-H\] ^--^          895.3978       895.3969       -1     ---            ---        ---        ---    GC
  96          19.556       22-Hydroxy-licorice-saponin G2               C~42~H~62~O~18~      \[M-H\] ^--^          853.3871       853.3863       -0.9   ---            ---        ---        ---    GC
  97          20.269       Licorice-saponin A3 (or isomer)              C~48~H~72~O~21~      \[M-H\] ^--^          983.4492       983.4493       0.1    ---            ---        ---        ---    GC
  98          20.551       Calycosin-7-O-β-D-glucoside                  C~22~H~22~O~10~      \[M-H\] ^--^          445.1148       445.1140       -1.8   ---            ---        ---        ---    DG/GC
  99          20.608       N-Methylcanadine                             C~21~H~24~NO~4~      ---                   ---            ---            ---    \[M+Na\] ^+^   377.1591   377.1598   1.9    HB
  100 *^b^*   20.857       Physcion                                     C~16~H~12~O~5~       \[M-H\] ^--^          283.0619       283.0612       -2.5   \[M+H\] ^+^    285.0751   285.0757   2.1    DH/SCG
  101         20.865       22β-Acetoxyl-glycyrrhizin                    C~44~H~64~O~18~      \[M-H\] ^--^          879.4027       879.4020       -0.8   ---            ---        ---        ---    GC
  102         21.130       Uralsaponin E                                C~42~H~60~O~17~      \[M-H\] ^--^          835.3799       835.3758       -4.9   ---            ---        ---        ---    GC
  103         21.313       Uralsaponin U/Uralsaponin N                  C~42~H~62~O~17~      \[M-H\] ^--^          837.3922       837.3914       -1     ---            ---        ---        ---    GC
  104         21.470       (6a*R*, 11a*R*)-3-Hydroxy-9, 10-             C~17~H~16~O~5~       ---                   ---            ---            ---    \[M+H\] ^+^    301.1070   301.1071   0.3    DG
                           dimethoxypterocarpan                                                                                                                                                     
  105         21.719       Phellodenol D                                C~17~H~18~O~5~       ---                   ---            ---            ---    \[M+H\] ^+^    303.1230   303.1227   -1     HB
  106         21.876       Shancigusin H                                C~49~H~62~O~23~      \[M-H\] ^--^          1017.3613      1017.3609      -0.4   ---            ---        ---        ---    SCG
  107         22.307       Laccaic acid D-8-O-(6′-O-cinnamoyl)-         C~31~H~26~O~13~      \[M-H\] ^--^          605.1307       605.1301       -1     ---            ---        ---        ---    DH
                           glucopyranoside                                                                                                                                                          
  108         22.539       (6R, 9S)-3-Oxo-α-ionol-β-D-                  C~19~H~30~O~10~S     \[M-H\] ^--^          449.1469       449.1487       4      ---            ---        ---        ---    DS
                           glucopyranoside sulfate                                                                                                                                                  
  109         22.597       Bicyclo \[3.1.0\] hexan-3-one                C~12~H~18~O~2~       ---                   ---            ---            ---    \[M+H\] ^+^    195.1366   195.1380   7.2    Dh
  110         22.920       Licorice-saponin G2                          C~42~H~62~O~17~      \[M-H\] ^--^          837.3932       837.3914       −2.1   ---            ---        ---        ---    GC
  111         23.244       (+) N-methylcorydine                         C~21~H~26~NO~4~      ---                   ---            ---            ---    \[M+Na\] ^+^   379.1740   379.1754   3.7    HB
  112         24.014       22*β*-Acetoxy-licorice-saponin B2            C~44~H~66~O~17~      \[M-H\] ^--^          865.4229       865.4227       −0.2   ---            ---        ---        ---    GC
  113         24.279       Macedonoside C                               C~42~H~62~O~16~      \[M-H\] ^--^          821.3972       821.3965       −0.9   ---            ---        ---        ---    GC
  114         24.487       Obaculactone                                 C~26~H~30~O~8~       ---                   ---            ---            ---    \[M+H\] ^+^    471.2009   471.2013   0.8    HB
  115 *^b^*   24.676       Rhein                                        C~15~H~8~O~6~        \[M-H\] ^--^          283.0258       283.0248       −3.5   \[M+H\] ^+^    285.0390   285.0394   1.4    DH
  116         24.702       Glycyrrhetic acid                            C~30~H~46~O~4~       ---                   ---            ---            ---    \[M+H\] ^+^    471.3467   471.3469   0.4    GC
  117         25.588       Glycyrflavoside C                            C~42~H~64~O~15~      \[M-H\] ^--^          807.4180       807.4172       −1     ---            ---        ---        ---    GC
  118         25.614       trans-Resveratrol                            C~14~H~12~O~3~       ---                   ---            ---            ---    \[M+H\] ^+^    229.0857   229.0859   0.9    TFL/HZ
  119 *^b^*   25.869       Glycyrrhizic acid                            C~42~H~62~O~16~      \[M-H\] ^--^          821.3975       821.3965       −1.2   ---            ---        ---        ---    GC
  120         27.652       Phytosphingosine                             C~18~H~39~NO~3~      ---                   ---            ---            ---    \[M+H\] ^+^    318.2991   318.3003   3.8    DG
  121         28.829       Octanal                                      C~8~H~16~O           ---                   ---            ---            ---    \[M+H\] ^+^    129.1266   129.1274   6.2    DS/Dh
  122 *^b^*   29.448       Emodin                                       C~15~H~10~O~5~       \[M-H\] ^--^          269.0465       269.0455       −3.7   \[M+H\] ^+^    271.0596   271.0601   1.8    DS/DH/SCG/HZ
  123         29.448       Z-11-hexadecenoic acid                       C~16~H~30~O~2~       \[M+CH~3~COO\] ^--^   313.2393       313.2384       −2.9   ---            ---        ---        ---    Dh
  124         29.458       2, 6-dimethoxy-4-(2'-propenyl) phenol        C~11~H~14~O~3~       ---                   ---            ---            ---    \[M+H\] ^+^    195.1016   195.1016   0      DS
  125         29.889       Ligustilide                                  C~12~H~14~O~2~       ---                   ---            ---            ---    \[M+H\] ^+^    191.1063   191.1067   2.1    DG
  126 *^b^*   30.254       Osthole                                      C~15~H~16~O~3~       ---                   ---            ---            ---    \[M+H\] ^+^    245.1173   245.1172   −0.4   DG/Dh
  127 *^b^*   31.116       Columbianadin                                C~19~H~20~O~5~       ---                   ---            ---            ---    \[M+H\] ^+^    329.1387   329.1384   −0.9   Dh
  128         31.271       9-Tetradecenoic acid                         C~14~H~26~O~2~       \[M+CH~3~COO\] ^--^   285.2081       285.2071       −3.5   ---            ---        ---        ---    Dh
  129         31.652       (E)-2-Hexenyl-β-D-glucopyranosyl-            C~18~H~32~O~11~      \[M-H\] ^--^          423.1860       423.1872       2.8    ---            ---        ---        ---    DS
                           (1/2)-β-D-glucopyranoside                                                                                                                                                
  130         31.917       α-Selinene                                   C~14~H~20~           \[M+HCOO\] ^--^       233.1554       233.1547       −3     ---            ---        ---        ---    CZ
  131         33.353       Dibutylphthalat                              C~16~H~22~O~4~       ---                   ---            ---            ---    \[M+H\] ^+^    279.1598   279.1591   −2.5   HZ
  132         34.563       Citronellyl acetate                          C~12~H~22~O~2~       ---                   ---            ---            ---    \[M+H\] ^+^    199.1698   199.1693   −2.5   CZ
  133         34.646       Litcubine                                    C~19~H~22~NO~4~      ---                   ---            ---            ---    \[M+H\] ^+^    329.1605   329.1622   5.2    HB
  134 *^b^*   34.834       Oleanolic acid                               C~30~H~48~O~3~       \[M-H\] ^--^          455.3532       455.3531       −0.2   ---            ---        ---        ---    WLX
  135         35.546       Tetradecanoic acid                           C~14~H~28~O~2~       \[M-H\] ^--^          227.2022       227.2017       −2.2   ---            ---        ---        ---    DS
  136         35.624       1,2-Benzenedicarboxylic acid                 C~24~H~38~O~4~       ---                   ---            ---            ---    \[M+H\] ^+^    391.2852   391.2843   −2.3   DS
                           diisooctyl ester                                                                                                                                                         
  137         36.192       Linoleate                                    C~18~H~32~O~2~       \[M-H\] ^--^          279.2340       279.2330       −3.6   ---            ---        ---        ---    DG
  138         36.325       Octadecanoic acid                            C~18~H~36~O~2~       \[M-H\] ^--^          283.2650       283.2643       −2.5   ---            ---        ---        ---    DG
  139         37.170       Hexadecanoic acid                            C~16~H~32~O~2~       \[M-H\] ^--^          255.2340       255.2330       −3.9   ---            ---        ---        ---    DS/DG/Dh/SCG

^a^ TFL, Smilacis Glabrae Rhizome; CS, Paeoniae Radix Rubra; HZ, Polygoni Cuspidati Rhizoma et Radix; SCG, Cremastrae Pseudobulbus; DH, Rhei Radix et Rhizoma; WLX, Clematidis Radix et Rhizome; Dh, Angelicae Pubescentis Radix; HB, Phellodendri Chinensis Cortex;CZ, Atractylodis Rhizome; GC, Glycyrrhizae Radix et Rhizome; DS, Codonopsis Radix; DG, Angelicae Sinensis Radix.

^b^ Components identified with reference compounds comparison.

Among them, 15 compounds (compounds **56**, **57**, **60**, **79**, **81**, **84**, **93**, **94**, **100**, **115**, **119**, **122**, **126**, **127,** and **134**) were identified as ferulic acid, polydatin, astilbin, paeoniflorin, atractylodin, liquiritin, chysophanol, aloe-emodin, physcion, rhein, glycyrrhizic acid, emodin, osthole, columbianadin, and oleanolic acid by comparing the retention time, quasi-molecular ions with authentic standards, respectively. While the others were tentatively deduced based on their high-accurate quasi-molecular ion such as \[M−H\]^−^, \[M+HCOO\]^−^, \[M+CH~3~COO\]^−^, \[M\]^+^, \[M+H\]^+^, and \[M+Na\]^+^ with those of the known published compounds recorded in the in-house library. Information regarding the 139 constituents, such as t~R~ (min), identification, formula, negative ion (m/z), positive ion (m/z), and botanical source, is offered in [**Table 1**](#T1){ref-type="table"}.

Network Pharmacology Analysis {#s3_2}
-----------------------------

### Gouty Arthritis-Related Targets Network Analysis {#s3_2_1}

The relationship among 175 disease genes from PPI were subjected to STRING. And a gene-gene interaction network was accordingly achieved. Then, disease targets of PPI with high confidence score (\>0.95) were screened for network construction and analysis ([**Figure 3**](#f3){ref-type="fig"}), 84 nodes and 171 edges were involved in this network. Among them, the central part notes connected by more than 4 edges, such as 19 in IL-6, 15 in IL-1β, 5 in CASP1, and 4 in NLRP3. It implies that these genes might be key nodes in this network.

![Gouty arthritis-related targets of protein-protein interaction (PPI) network (Confidence score \>0.95, Node size represent the degree).](fphar-10-01626-g003){#f3}

### Potential Target Genes and Network Construction {#s3_2_2}

The target genes related to gouty arthritis and compounds were got from associated databases, and 51 overlapping genes were identified by matching the aforementioned genes. Then compound-potential targets-disease network constructed by Cytoscape was shown in [**Figure 4**](#f4){ref-type="fig"}, which comprise of 132 nodes (1 disease node, 51 potential target nodes, and 80 compound nodes) and 236 edges. From this network, we can conclude that glycyrrhizic acid, amurenlaetone B, and macedonoside C may be the main components of JSCBR in treating gouty arthritis due to higher degree.

![Compound-potential targets-disease network (Blue diamond represents compound target; red circle represents pathway; purple hexagon represents disease).](fphar-10-01626-g004){#f4}

### Potential Target Gene-Related Pathway Analysis {#s3_2_3}

To better understand the signaling pathways and functions of these potential target genes, we performed functional enrichment analysis using KEGG pathways. The identified pathways and genes in which they are involved are shown in [**Figure 5**](#f5){ref-type="fig"} and [**Table 2**](#T2){ref-type="table"} (p \< 0.05). NOD-like receptor signaling pathway (hsa04621) is ranked first, which has 10 genes involved. In our present research, NRLP3/ASC/CASP1/IL1B was selected for experimental verification.

![Network of pathways and related genes (Green "V" represents pathways; red circle represents pathway; node size represents the degree).](fphar-10-01626-g005){#f5}

###### 

Functions of potential target genes based on KEGG pathway analysis.

  No   Term                                               P Value     Genes
  ---- -------------------------------------------------- ----------- ----------------------------------------------------------------------
  1    hsa04621: NOD-like receptor signaling pathway      1.24E-11    MAPK1, CARD8, IL6, TNF, CCL2, RELA, CXCL2, IL1B, NFKB1, CASP1, NLRP3
  2    hsa04620: Toll-like receptor signaling pathway     7.54E-06    MAPK1, IL6, TNF, RELA, IL1B, NFKB1, TLR4, CD14
  3    hsa04060: Cytokine-cytokine receptor interaction   5.65E-04    IL4, CSF2, IL6, TNF, CCL2, CCL20, CXCL2, IL1B, TGFB1
  4    hsa04623: Cytosolic DNA-sensing pathway            6.88E-04    IL6, RELA, IL1B, NFKB1, CASP1
  5    hsa04660: T cell receptor signaling pathway        0.0011312   IL4, CSF2, MAPK1, TNF, RELA, NFKB1
  6    hsa04664: Fc epsilon RI signaling pathway          0.0025462   IL4, CSF2, MAPK1, TNF, SYK
  7    hsa04062: Chemokine signaling pathway              0.011938    MAPK1, CCL2, CCL20, RELA, CXCL2, NFKB1
  8    hsa04010: MAPK signaling pathway                   0.0132372   MAPK1, TNF, RELA, IL1B, NFKB1, CD14, TGFB1
  9    hsa04920: Adipocytokine signaling pathway          0.0132749   PPARA, TNF, RELA, NFKB1
  10   hsa04662: B cell receptor signaling pathway        0.0179629   MAPK1, RELA, NFKB1, SYK
  11   hsa04210: Apoptosis                                0.0265251   TNF, RELA, IL1B, NFKB1

Experimental Validation Using Molecular Cell Biology {#s3_3}
----------------------------------------------------

### Effect of JSCBR Extracts on Cell Viability {#s3_2_4}

The induction effect of MSU was evaluated *in vitro* with a CCK-8 assay and shown in [**Figure 6A**](#f6){ref-type="fig"}. Notably, MSU acted as the strongest inducer decreased the viabilities of THP-1 cell in a concentration-dependent manner. Since the relatively low viability was observed in cells exposed to MSU with dosages greater than or equal to 200 μg/ml, 150 μg/ml was the optimum induction dosage in further experiments. For antiinflammatory activity, THP-1 cells treated with JSCBR extracts from 1 to 5 mg/ml exhibited viability of 67.8%\~80.6% ([**Figure 6B**](#f6){ref-type="fig"}). Since no further antiproliferation effect was observed in cells exposed to 4 and 5 mg/ml, the concentrations of extracs were defined to 1, 2, and 3 mg/ml for western Blot verification.

![Effects of Jiang-Suan-Chu-Bi recipe (JSCBR) extracts on monosodium urate (MSU)-induced THP-1 cell viability. **(A)** THP-1 cells were exposed to MSU at various concentrations for 24 h. **(B)** Protective effects of JSCBR extracts on the viabilities of MSU-induced THP-1 cells. Cell viability was assessed by CCK-8 assay and expressed relative to untreated control cells. \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 versus control group.](fphar-10-01626-g006){#f6}

Western Blot Analysis {#s3_4}
---------------------

In order to validate the action mechanism of JSCBR screened out by phytochemistry-based network pharmacology, protein expression of ASC, caspase-1, IL-1β, and NLRP3 was examined by Western Blot Analysis. Compared with a control group, the expression of these three proteins in the model group was significantly increased ([**Figure 7**](#f7){ref-type="fig"}, P \< 0.01), while these protein expression changes were attenuated by treatment with colchicine and different concentrations of JSCBR extracts (1, 2, and 3 mg/ml) ([**Figure 7**](#f7){ref-type="fig"}, P \< 0.01). The results suggested that the antiinflammation of JSCBR on gouty arthriris was associated with inhibition of ASC, caspase-1, IL-1β, and NLRP3 protein expression, which belongs to NOD-like receptor signaling pathway.

![Jiang-Suan-Chu-Bi recipe (JSCBR) extracts protect THP-1 cells against monosodium urate (MSU)-induced inflammation by affecting the expression of proteins from the NOD-like receptor signaling pathway. **(A)** Effects of JSCBR extracts on ASC, caspase-1, IL-1β, and NLRP3 protein levels in MSU-induced THP-1 cells based on the western blotting assay; **(B)** Statistical analysis of the effects of JSCBR extracts on protein expressions levels. Data are presented as the mean ± SD (*n* = 3), \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 versus control group. ^\#\#^ *p* \< 0.01, ^\#\#\#^ *p* \< 0.001, ^\#\#\#\#^ *p* \< 0.0001 versus model group. ^&^ *p* \< 0.05, ^&&&^ *p* \< 0.001, ^&&&&^ *p* \< 0.0001 versus colchicine group.](fphar-10-01626-g007){#f7}

Discussion {#s4}
==========

In recent years, prevalence of gouty arthritis annually increased with the continuous improvement of people's living standards. Although some achievement has been made in reducing the mortality of the disease, it still imposed a huge economic burden on patients and society which also reduced the quality of life of patients. Colchicine, glucocorticoids, and nonsteroidal antiinflammatory drugs, acted as the current mainstay drugs for gouty arthritis, have been controversial due to their various side effects. It is very necessary to develop new drugs with remarkable curative effect and little side effect.

The pathogenesis of gouty arthritis is classified in the "damp-heat" category according to TCM theory, the therapeutic principles of "clearing heat, dispelling dampness, dissipating stasis, and relieving pain" should be used. JSCBR, a formula prescribed according to abovementioned principles and utilization frequency and made up of 12 kinds of herbs, which has been effective in treating gouty arthritis. However, its "multicomponents", "multitargets" and "multipathways" features make it much difficult to decipher the molecular mechanisms of JSCBR in the treatment of gouty arthritis from a systematic perspective. In this study, we combined phytochemistry, network pharmacology and molecular cell biology to evaluate the effective components and possible molecular mechanisms of JSCBR in the treatment of gouty arthritis ([@B3]).

Firstly, chemical profile of JSCBR was characterized for the first time, which lays the material foundation for the follow-up network pharmacology research. Network pharmacological analysis of JSCBR identified 51 potential target nodes, 80 compounds, and 11 related pathways related to gouty arthritis. Among the target compounds linked to the network, two triterpenoid saponins glycyrrhizic acid (Compound **119**) from Glycyrrhizae Radix et Rhizome and macedonoside C (Compound **113**) from Rhei Radix et Rhizoma, as well as a phenolic acid amurenlaetone B (Compound **47**) from Phellodendri Chinensis Cortex may be the effective components of JSCBR in treating gouty arthritis due to higher degree. The two triterpenoid saponins could act at least in part, as a glucocorticoid-like drug due to the similar chemical structure related to glucocorticoids. Additionally, reports have provided evidence that treatments with these two types of components can alleviate the symptoms of gouty arthritis by exerting antiinflammatory and antioxidant pharmacological effects ([@B11]; [@B24]; [@B8]).

Among the 51 putative targets and 11 related pathways of JSCBR associate with gouty arthritis, it was discovered that IL-6, IL-1β, CASP1, and NLRP3 were relatively important targets evaluated by topological parameters, which are involved in NOD-like receptor, Toll-like receptor, cytokine-cytokine receptor interaction, and cytosolic DNA-sensing signaling pathways. Among which, NOD-like receptor signaling pathways was ranked first. Thus, a further confirmation was selected for further verification.

As illustrated in some research studies, NOD-like receptor protein-3 inflammasome (NLRP3) and toll-like receptor-4 (TLR4) plays an important role during gouty arthritis ([**Figure 8**](#f8){ref-type="fig"}). NLRP3 inflammasome, an assembly composed of NLRP3, apoptosis-associated speck-like protein (ASC) containing a C-terminal caspase recruitment domain (CARD) and the effector procaspase-1, which can be activated by a "danger signal" crystal MSU. Once activated, NLRP3 oligomerizes and recruits the ASC adaptor protein and procaspase-1 sequentially. Caspase-1 was then activated and proteolytic cleavaged by the complex, resulting in specialized maturation and secretion of IL-1β and IL-18. In addition, MSU could also be recognized by Toll-like receptors, Toll-like receptor pathway could active the NLRP3 inflammasome complex and further induce an activation of inflammatory cascade ([@B14]; [@B20]).

![Overview of potential mechanisms underlying the protective effects of Jiang-Suan-Chu-Bi recipe (JSCBR) on monosodium urate (MSU)-induced gouty arthritis.](fphar-10-01626-g008){#f8}

Our experiments in molecular cell biology had shown that the expressions of ASC, caspase-1, and IL-1β were significantly increased in the MSU-induced THP-1 cells, while they were significantly downregulated after treatment with JSCBR, which is consistent with network prediction. Therefore, it is speculated that NOD-like receptor signaling pathway is involved in the pathogenesis of gouty arthritis, and JSCBR could treat gouty arthritis by negative regulation of the inflammatory response. Besides, other potential mechanisms of JSCBR explored by above integrated strategy need for further investigation.

Conclusion {#s5}
==========

In the current study, an integrated approach based on chemical profile, network pharmacology and experimental support using molecular cell biology were carried out to reveal the therapeutic composition and mechanisms of JSCBR against gouty arthritis. Following identification of 139 chemical constituents in JSCBR by UHPLC-QTOF MS, 175 disease genes, 51 potential target nodes, 80 compounds, and 11 related pathways were achieved by network pharmacology analysis. Potential key targets NRLP3/ASC/CASP1/IL1B that associated with the negative regulation of in NOD-like receptor signaling pathway were further verified in monosodium urate-induced THP-1 cells, and a plausible mechanism for the multitarget effects of JSCBR on gouty arthritis was consequently proposed ([**Figure 8**](#f8){ref-type="fig"}). Taken together, our results provide a comprehensive insight into therapeutic composition and mechanistic of JSCBR, which make beneficial exploration for the research and development of traditional Chinese herbal formula.
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